This paper examines the implications of the IMF’s April 2024 macro-fiscal forecast updates on government health expenditure (GHE) across 170 economies through 2029, covering nearly all years remaining to achieve the Sustainable Development Goals (SDGs). The findings reveal wide disparities in gove...rnments' capacities to increase health spending, with differences not only observed across income groups but also within them. Primary concerns focus to two groups of low- and lower middleincome
countries: the first group is projected to experience a contraction in real per capita GHE from 2019 and 2029, threatening to reverse progress toward the health SDG targets, while the other group faces stagnation in real per capita GHE, greatly limiting advancement. The insights presented are crucial for health policymakers and their external partners to respond to evolving macro-fiscal circumstances and stabilize investment growth in health. While increasing the priority of health in spending is a key policy option, it will not be sufficient on its own. Effective responses also
require improving spending efficiency and addressing broader fiscal challenges. Without decisive action, many countries have little chance of achieving the health SDGs.
more
The world is facing a sustainable development crisis. The 2024 Financing for Sustainable Development Report: Financing for Development at a Crossroads finds that financing challenges are at the heart of the crisis and imperil the SDGs and climate action. The window to rescue the SDGs and prevent a c...limate catastrophe is still open but closing rapidly. Financing gaps for sustainable development are large and growing – the estimates by international organizations and others are coalescing around $4 trillion additional investment needed annually for developing countries. This represents a more than 50% increase over the pre-pandemic estimates. Meanwhile, the finance divide has not been bridged, with developing countries paying around twice as much on average in interest on their total sovereign debt stock as developed countries. Many countries lack access to affordable finance or are in debt distress. Weak enabling environments are preventing progress. Average global growth has declined, while policy and regulatory frameworks still do not set appropriate incentives. Public budgets and spending is not fully aligned with SDGs. Private investors are not incentivised to invest enough in SDGs and climate action. The world is at a crossroads. This is the last chance to correct course if we want to achieve the SDGs by the 2030 deadline. Only an urgent, large-scale and sustainable investment push can help us achieve our global goals. Next year’s Fourth International Conference on Financing for Development in 2025 will be a once in 80-year opportunity to support coherent transformation of financing.
more
Access to medicines is essential for attainment of universal health coverage, which is central to achievement of the health-related Sustainable Development Goals. Controlled medicines include those such as opioids, benzodiazepines, barbiturates, amphetamines and others with identified or emergent cl...inical indications. WHO recognizes that these medicines are necessary for pre- and post-operative care, for sedation, for the management of both acute and chronic pain, for palliative care, as anticonvulsants (anti-epileptics), for the management of anxiety disorders and for the management of substance use disorders, including as opioid agonist therapy (OAT).
more
"Some of the problems with our current drug policies stem from the fact that these policies have been largely bifurcated between two different and often contradictory approaches. One treats drug use as a crime that cannot be tolerated and should be punished; the other views addiction as a chronic re...lapsing health or behavioral condition requiring ongoing treatment and support. Neither of these views is all encompassing—it should be recognized that there are patterns of drug use that do not result in significant harm or health problems and therefore require no intervention. The public health approach presented here takes the view that our focus should be on the harm caused by drug use and the harm caused by our policy responses to it. We have focused specifically on illicit drugs, not because they are by themselves more harmful (in fact, tobacco causes more morbidity and mortality than any illicit drug), but because it has become increasingly clear that our current policies to manage illicit drugs are failing."
more
French version of "Developing Pharmacy Practice" - WHO/FIP Joint handbook - Ce manuel expose un nouveau paradigme de pratique pharmaceutique. Il a pour but de guider les enseignants en pharmacie pour qu’ils intègrent cette nouvelle pratique pharmaceutique, de former les étudiants ...en pharmacie et d’aider les pharmaciens en exercice à actualiser leurs compétences. Ce manuel, qui rassemble outils pratiques et théorie, a été conçu pour répondre à un besoin précis : définir et développer les soins pharmaceutiques, ainsi que de permettre une meilleure compréhension de ce concept à tous les niveaux.
more
Background: Cardiovascular disease (CVD), mainly heart attack and stroke, is the
leading cause of premature mortality in low and middle income countries (LMICs).
Identifying and managing individuals at high risk of CVD is an important strategy to prevent and control CVD, in addition to multisector...al population-based interventions to reduce CVD risk factors in the entire population.
Methods: We describe key public health considerations in identifying and managing individuals at high risk of CVD in LMICs.
Results: A main objective of any strategy to identify individuals at high CVD risk is to maximize the number of CVD events averted while minimizing the numbers of
individuals needing treatment. Scores estimating the total risk of CVD (e.g. ten-year risk of fatal and non-fatal CVD) are available for LMICs, and are based on the main CVD risk factors (history of CVD, age, sex, tobacco use, blood pressure, blood cholesterol and diabetes status). Opportunistic screening of CVD risk factors enables identification of persons with high CVD risk, but this strategy can be widely applied in low resource settings only if cost effective interventions are used (e.g. the WHO Package of Essential NCD interventions for primary health care in low resource settings package) and if treatment (generally for years) can be sustained, including continued availability ofaffordable medications and funding mechanisms that allow people to purchase medications without impoverishing them (e.g. universal access to health care). Thisalso emphasises the need to re-orient health systems in LMICs towards chronic diseases management.
Conclusion: The large burden of CVD in LMICs and the fact that persons with high
CVD can be identified and managed along cost-effective interventions mean that
health systems need to be structured in a way that encourages patient registration, opportunistic screening of CVD risk factors, efficient procedures for the management of chronic conditions (e.g. task sharing) and provision of affordable treatment for those with high CVD risk. The focus needs to be in primary care because that is where most of the population can access health care and because CVD programmes can be run effectively at this level.
more
Dieser Bericht enthält eine neue Strategie für Investitionen in die Gesundheit als Beitrag zur Wirtschaftsentwicklung, vor allem in den ärmsten Ländern der Welt, auf der Grundlage einer neuen globalen Partnerschaft zwischen sich entwickelnden und entwickelten Ländern. Zügiges und mutiges Hande...ln könnte zum Ende dieser Dekade mindestens 8 Millionen
Menschenleben pro Jahr retten, die Lebensdauer und die Leistungsfähigkeit der Armen erhöhen und ihre wirtschaftliche Lage verbessern Hierfür wären zwei wichtige Initiativen zu ergreifen: eine deutliche Erhöhung der Mittel, die für Gesundheit ausgegeben werden,sowohl durch die armen Länder als auch durch die Geber und eine Beseitigung der nichtfinanziellen Hindernisse, die arme Länder in ihrer Fähigkeit zur Bereitstellung von Gesundheitsdiensten einschränken
more
Spanish version of "Developing Pharmacy Practice" - WHO/FIP Joint handbook -
Este manual de introducción marca un nuevo paradigma en la práctica de farmacia. Intenta guiar a los formadores en atención farmacéutica para educar a los estudiantes de farmacia y a los farmacéuticos ya estableci...dos en la actualización de sus conocimientos. Este manual, que ofrece teoría y ejemplos prácticos, ha sido escrito como respuesta a la necesidad de definir, desarrollar y agrupar todos los conocimientos actuales sobre la atención farmacéutica.
more
Vaincre le Sida par Tous, une Riposte pour Tous
Le Plan Stratégique National de Lutte contre le Sida (PSN) 2018-2022 sera le cadre unique pour tous les acteurs de la lutte contre le sida au Sénégal. Il constitue la référence pour la programmation des activités aux niveaux national et régio...nal, et sera l’outil indispensable pour l’harmonisation et l’alignement des partenaires. Ce plan traduit la vision et les engagements du Gouvernement du Sénégal à maintenir les acquis et à orienter la riposte vers l’élimination du sida en utilisant toutes les opportunités et ressources, aussi bien domestiques qu’internationales.
more
Le rapport 2016 fait état de la situation du VIH dans notre pays en rappelant les enjeux et défis en rapport avec le contexte international. Il renseigne également sur la situation du VIH, les financements et programmes mis en œuvre et les résultats obtenus.
The Community-based Health System Model Series briefs identify and discuss critical health system inputs and processes that have contributed to the implementation and expansion of community-based service delivery in different countries.
Countries were selected for their geographic diversity, type o...f service delivery model, and programmatic scale-up.
This brief reviews Malawi’s community health model to inform future policy, program design, and implementation in other countries.
more
Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported ...serious adverse events (SAEs).
more